Brian Casey’s Post

In This Issue  AI-assisted prenatal ultrasound ProMED is broke - and why you should care The pandemic delayed cancer screening - and it matters #sensitiveandspecific #diagnostics #diagnostictesting #biomedicaldiagnostics #AI #aiimaging #prenatalultrasound #sarscov2 #ProMED #pandemic #cancerscreening #cancerdiagnosis #bacterialprofile #EG.5 #Eris

𝐍𝐨𝐧-𝐒𝐦𝐚𝐥𝐥 𝐂𝐞𝐥𝐥 𝐋𝐮𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 (𝐍𝐒𝐂𝐋𝐂) 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐆𝐥𝐨𝐛𝐚𝐥 𝐒𝐢𝐳𝐞, 𝐒𝐡𝐚𝐫𝐞 & 𝐅𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝟐𝟎𝟑𝟒 ▶𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅: https://lnkd.in/dmizz_AE The Non-Small Cell Lung Cancer (NSCLC) market is projected to exceed USD 33.5 billion by 2030, growing at a CAGR of 11.70% from USD 12.4 billion in 2021. NSCLC, comprising about 85% of all lung cancer cases, includes various epithelial lung cancers apart from Small Cell Lung Cancer (SCLC). These cancers can arise anywhere from the central bronchial epithelial cells to the terminal alveoli, often found in both smokers and non-smokers. Common symptoms encompass chest pain, wheezing, chronic bronchitis, and fatigue. The market growth is driven by increasing global incidences of lung cancer, particularly NSCLC, prompting key players to innovate and enhance therapeutic options. Investments in research and development are further propelling market expansion, addressing the critical need for effective NSCLC treatments globally. 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧: ▶𝐁𝐲 𝐡𝐢𝐬𝐭𝐨𝐥𝐨𝐠𝐲: large cell carcinoma cell carcinoma, adenocarcinoma or squamous, SCC. ▶𝐁𝐲 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭: chemotherapy, Radiation, surgery. ▶𝐁𝐲 𝐑𝐞𝐠𝐢𝐨𝐧: North America, Europe, Asia Pacific, Latin America, Middle East & Africa (MEA). 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐜𝐨𝐯𝐞𝐫𝐞𝐝:          IBM, FIDELITY HEALTH SERVICES, Wave Health Technologies, Lexalytics, an InMoment Company, Microsoft, Inovalon, Amazon Web Services (AWS), Google, Dolby Laboratories, and Cerner Corporation #NSCLC #LungCancer #CancerResearch #LungHealth #Oncology #CancerTreatment #Immunotherapy #PrecisionMedicine #TargetedTherapy #ClinicalTrials #CancerAwareness #LungCancerAwareness #HealthcareInnovation #PersonalizedMedicine #Survivorship #HealthTech #MedicalResearch #PatientCare #Oncologist #HopeForACure

Breaking News: We're thrilled to share new groundbreaking clinical data supporting OvaWatch's use in assessing ovarian cancer risk for women with adnexal masses! This new data, featured in Frontiers in Medicine, showcases the potential impact of the neural network powered MIA3G multivariate index assay on surgical decisions for women with adnexal masses. The data shows that this innovative tool could have led to a 62% overall reduction in avoidable surgeries in the studied population, with specific reductions of 59% among asymptomatic patients and 77% among premenopausal patients. Read the study and PR announcement here: https://lnkd.in/e4zjdrKG #OvarianCancer #HealthTech #MedicalInnovation #AIHealthcare #OvaWatch #AspiraWomensHealth

🤖💡 Artificial Intelligence is revolutionizing medicine. Researchers from the University of Michigan 🏛️ have developed K-ECAN, a tool that could predict esophageal and stomach cancer up to three years before diagnosis. This provides crucial time for effective treatments and a better quality of life for patients. This breakthrough represents an exciting milestone in healthcare for patients. If you want to learn more about this innovative technology, click on the following link! https://lnkd.in/ekr3dwjZ 💻🔍 #AI #Healthcare #Diagnosis #Cancer #MedicalResearch

Great news from the healthcare sector! AI tools are revolutionising lung cancer diagnosis in NHS hospitals, promising faster and more accurate results. This technology is set to enhance patient care, read the full article here: https://lnkd.in/e9sQXbEc #HealthTech #AIInHealthcare #Innovation #NHS #MedicalTechnology

⭐️⭐️ Breakthrough in womb cancer detection ⭐️⭐️ This article has made my heart sing! A new, non invasive test could radically change the diagnostic pathway for the 800,000 women who are investigated for abnormal vaginal bleeding every year. WiD-9EC ( not Elon Musk’s latest child) is a non invasive test which could avoid the need for multiple referrals to outpatients for invasive, expensive and often traumatic ultrasounds, hysteroacopies and biopsies. There are over 700,000 women on gynae waiting lists in the U.K. with some of the highest waiting times of all clinical specialities. This could remove the need for many of these appointments, improve time to diagnose and reduce waiting lists. The Eve Appeal and the Institute for Women’s Health at UCL supported by Horizon 2020 have made what feels like an incredible break through. With the development of Women’s Health Hubs across the UK, we have the perfect opportunity to trial at scale these new pathways 💃🏼💃🏼💃🏼 #womenshealthcare #womwnshealthmatters #womenshealthhubs #nhswomen

There are many risk predictor models and biomarkers on the horizon to better direct lung cancer screening and whichever ones are most useful will fit nicely in the shared decision making workflow. Per Heather Wakelee, MD, Julie Tsu-yu Wu, MD, PhD and Summer Han, PhD of Stanford University School of Medicine: "Several lung cancer risk prediction models incorporate demographic, clinical, and environmental risk factors for lung cancer. "The dominant risk factors for lung cancer include smoking history, male sex, African American race, age, personal and family history of cancer, exposure to asbestos and radon, and the presence of chronic lung disease. "Various combinations of these factors are used in different models, many of which have been externally validated in independent data sets. "To inform the 2021 USPSTF recommendation update, the Cancer Intervention and Surveillance Modeling Network (CISNET) modeling group compared the performance of three major risk prediction models—the PLCOm2012 model, 11 LCDRAT, 12 and Bach13—versus the current 2021 USPSTF guidelines in a simulated US birth cohort. "The modeling study showed that risk model-based screening strategies would reduce lung cancer mortality more effectively than the 2021 USPSTF criteria but increased overdiagnosis. "Biomarkers, which include DNA, proteins, and hormone levels, could potentially be useful in the early detection of cancer and may serve as a useful adjunct to risk prediction models on the basis of clinical factors. "However, most biomarker risk prediction models for lung cancer lack validation. "Ideally, individuals would decide on screening on the basis of an understanding of the risks and benefits of screening and probabilities of cancer. "Such expertise, however, is not often accessible in clinics nor among the general population, and historically, decision aids on the basis of risk prediction models are infrequently used in clinical practice. "While it remains to be seen how risk prediction models and biomarkers will ultimately be incorporated into lung cancer screening, it is evident that they have great potential to improve personalized shared decision making. Improving lung cancer screening efficiency for all patients is the Oatmeal Health mission. With a new #HEDIS measure on the horizon from NCQA, we would like to help FQHCs be prepared. We are ready to help. Please send Jonathan or me a note if you'd like to learn more about Oatmeal Health. #primarycare #radiology #lungcancerscreening #FQHC Do you work at an FQHC and want to learn more, please check our partner page website: https://lnkd.in/gh8y5uJC Thank you to the American Society of Clinical Oncology (ASCO) for the article: https://lnkd.in/ecZTrJWc

Big news in healthcare innovation🧬 64 NHS trusts across England are set to integrate AI in diagnosing and treating lung cancer—representing a significant leap forward in utilizing AI to enhance medical diagnosis. AI's role will be to analyze chest X-rays and CT scans, streamlining the process to diagnose lung cancer more effectively. With over 600,000 chest X-rays performed monthly in England, this technology could be a game-changer in terms of accuracy and speed. Jen Brogan MA at PharmaTimes Media Ltd goes further in-depth about this initiative and the UK's broader strategy to embed AI in healthcare here: https://lnkd.in/e9sQXbEc #BioTech #LungCancer #AI

Do we really need doctor's hands in our vaginas? The US Preventive Services Task Force (USPSTF) has found insufficient evidence to assess the balance of benefits and harms of performing pelvic exams for asymptomatic women. The American College of Obstetricians and Gynecologists (ACOG) recommends pelvic exams only when a patient has symptoms or a medical history that requires it. So if we were able to self-collect cells for cervical cancer screening at home, could this eliminate the pelvic exam for most women and make screening more accessible, especially for underserved populations? Find out how BD is working on the first self-collection kit for the US in my recent ForbesWomen article. #cancer #diagnostics #womenshealth #femtech #femhealth #accessibility #cervicalcancer #athometesting #innovation

💜 Grateful and honored to have been invited to talk about the risk of #suddencardiacarrest in #cardiooncology at this year's Seattle Sudden Cardiac Death Symposium organized by Dr. Nazem Akoum and Dr. Jeanne Poole. 🗝️ Key take home points: 🔺 Sudden cardiac death (SCD) SCD risk differs among different cancer types. More studies needed to define SCD risk stratification in cancer patients and survivors. 💊 Risk observed in a retrospective study of ~8,400 patients with all different types of #cancer was close to risk of SCD in patients with #heartfailure with reduced ejection fraction (one of the two main subtypes of heart failure) managed with modern heart failure medications. 💊 New types of cancer therapies, e.g. immunotherapy and other targeted therapies, come with unclear SCD risk. 🔺Growing number of studies showing pulseless electrical arrest (PEA)/asystole as more frequent mechanisms vs. VT/VF. Heart Rhythm Society University of Washington University of Alabama at Birmingham Harvard University John Michael Maier Mpirik (Acquired by Tempus AI) Tempus AI Medtronic Cardiac and Vascular Karen Shehade American Heart Association American College of Cardiology WASHINGTON CHAPTER OF THE AMERICAN COLLEGE OF CARDIOLOGY Sudden Cardiac Arrest Foundation Sudden Cardiac Arrest Association Sudden Cardiac-death Awareness Research Foundation CardioOne International Cardio-Oncology Society The US Oncology Network Oncology Insights Catalyst Oncology Cancer University Cancer Tech Accelerator NCI Division of Cancer Treatment and Diagnosis #medicine #science #evidencebasedpractice #evidencebasedmedicine #healthcarequality #patientcare #cardiology #cardiooncology